Oruka Therapeutics, Inc.
ORKA
Jodie situation report
Oruka Therapeutics, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 12 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.
- ORKA's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if ORKA's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind ORKA
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
MLTXMoonLake ImmunotherapeuticspartnerMar 12, 2026 ▾
“These include the biologic sonelokimab from MoonLake Immunotherapeutics targeting IL-17A/F, and several oral agents in development, including JNJ-2113 (icotrokinra) from Janssen targeting the IL-23 receptor, DC-853 (simepdekinra) from Eli Lilly targeting IL-1…”
HALOHalozyme Therapeutics, Inc.partnerMay 13, 2026 ▾
“On May 1, 2026, the Company and Halozyme Hypercon, Inc.”
RSReliance, Inc.partnerNov 12, 2025 ▾
“Risks Related to Our Reliance on Third Parties We currently rely on licensing arrangements with Paragon through the License Agreements.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 3 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
ORKA is currently a Follower in the organic co-movement group Industrial Equipment & Services. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for ORKA; it is not active in the latest market snapshot.